Paykel Eugene S
Department of Psychiatry, University of Cambridge, Cambridge, UK.
Int J Neuropsychopharmacol. 2007 Feb;10(1):131-6. doi: 10.1017/S1461145706006912. Epub 2006 Jun 20.
This paper reviews recent advances in application of cognitive therapy (CBT) to a therapeutic problem in depression. Modern follow-up studies indicate that, in spite of the efficacy of pharmacotherapy, relapse and recurrence rates in some depressed patients remain high. This does not appear mainly due to failure to receive medication, but to reflect intractability of the disorder. In acute treatment, psychological treatments, although beneficial, are less cost-effective than antidepressants, due to high costs of therapists. Benefit which lasts longer, particularly if combined with medication, may therefore be particularly valuable. There have now been seven randomized controlled trials of cognitive therapy designed specifically to test relapse and recurrence prevention. All have shown significant benefit, which lasts beyond the cessation of therapy. The effect appears to be more on preventing symptom return than on lessening current symptoms, to summate well with continuation and maintenance antidepressant, and not to be due simply to enhanced medication adherence. Incorporation into routine clinical practice is now appropriate and recommendations are proposed.
本文综述了认知行为疗法(CBT)在抑郁症治疗问题应用方面的最新进展。现代随访研究表明,尽管药物治疗有效,但一些抑郁症患者的复发率仍然很高。这似乎主要不是因为未接受药物治疗,而是反映了该疾病的难治性。在急性治疗中,心理治疗虽然有益,但由于治疗师成本高昂,其性价比低于抗抑郁药物。因此,持续时间更长的益处,特别是与药物治疗相结合时,可能特别有价值。目前已有七项专门设计用于测试预防复发的认知疗法随机对照试验。所有试验均显示出显著益处,且在治疗停止后仍持续存在。这种效果似乎更多地体现在预防症状复发而非减轻当前症状上,与持续和维持性抗抑郁药物效果良好,并非仅仅归因于提高了药物依从性。现在将其纳入常规临床实践是合适的,并提出了相关建议。